{"filing":{"accession_number":"0001034842-26-000045","cik":"0001034842","ticker":"RIGL","company_name":"RIGEL PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"rigl-20260625.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/rigl-20260625.htm"},"events":[{"id":15491,"run_id":13819,"accession_number":"0001034842-26-000045","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The disclosure centers on the appointment of Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals, effective July 1, 2026. While the filing also mentions Dr. Hannah's concurrent resignation from the Board and the departure of the prior CMO, Lisa Rojkjaer, the principal action disclosed is the appointment of a named executive officer to a C-suite position. This is material to investors as it affects the Company's senior leadership and medical strategy.","company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13285,"accession_number":"0001034842-26-000045","item_number":"5.02","item_title":"Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on the appointment of Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals, effective July 1, 2026. While the filing also mentions Dr. Hannah's concurrent resignation from the Board and the departure of the prior CMO, Lisa Rojkjaer, the principal action disclosed is the appointment of a named executive officer to a C-suite position. This is material to investors as it affects the Company's senior leadership and medical strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:14:43.793062+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13285,"accession_number":"0001034842-26-000045","item_number":"5.02","item_title":"Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on the appointment of Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals, effective July 1, 2026. While the filing also mentions Dr. Hannah's concurrent resignation from the Board and the departure of the prior CMO, Lisa Rojkjaer, the principal action disclosed is the appointment of a named executive officer to a C-suite position. This is material to investors as it affects the Company's senior leadership and medical strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:14:43.793062+00:00","company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","filing_date":"2026-07-01"}]}